Background
Methods
Study population
Western blot analysis
Statistical analysis
Results
Low SUV39H1 expression was associated with high blood neutrophil counts
Variables | Low SUV Exp. (n = 15) | High SUV Exp. (n = 15) | p value |
---|---|---|---|
Male, n (%) | 14 (93) | 15 (100) | 1 |
Age, years; median (IQR) | 71 (64–77) | 70 (62–74) | 0.561 |
BMI; median (IQR) | 24 (23.2–26.2) | 22.7 (19.9–24.6) | 0.141 |
Cigarette smoking, n (%) | 0.413 | ||
Current smoker | 5 (33) | 8 (53) | |
Ex-smoker | 7 (47) | 6 (40) | |
Never smoker | 3 (20) | 1 (7) | |
Comorbidities, n (%) | 0.919 | ||
Heart failure | 2 (13) | 0 (0) | |
Coronary artery disease | 3 (20) | 4 (27) | |
Pulmonary hypertension | 4 (27) | 2 (13) | |
Lung cancer | 0 (0) | 0 (0) | |
Anxiety/depression | 1 (7) | 1 (7) | |
Osteoporosis | 0 (0) | 1 (7) | |
Malnutrition (BMI < 20) | 2 (13) | 4 (27) | |
Diabetes mellitus | 1 (7) | 2 (13) | |
OSA | 1 (7) | 1 (7) | |
Anemia | 2 (13) | 2 (13) | |
Lung fibrosis | 1 (7) | 0 (0) | |
Charlson comorbidity Index score; median (IQR) | 5 (3–5) | 4 (4–6) | 0.833 |
Hemogram values; median (IQR) | |||
Leukocyte count | 7800 (6300–9200) | 6600 (5950–7200) | 0.110 |
Neutrophil, % | 65 (60–71) | 59 (52–61) | 0.015* |
Eosinophil, % | 2 (1–3) | 2 (2–4) | 0.125 |
E/N Ratio, % | 3.6 (1.7–4.7) | 4.7 (3.7–7.1) | 0.071 |
Pulmonary function tests; median (IQR) | |||
Post bronchodilator FEV1/FVC,% | 62 (50–65) | 60 (55–64) | 0.868 |
Post bronchodilator FEV1, % | 57 (35–67) | 55 (40–73) | 0.934 |
COPD subtypes, n (%) | 0.966 | ||
Stage 1 | 2 (13) | 2 (13) | |
Stage 2 | 8 (54) | 7 (47) | |
Stage 3 | 2 (13) | 3 (20) | |
Stage 4 | 3 (20) | 3 (20) | |
ACO, n (%) | 0 (0) | 1 (6.7) | 1 |
Exacerbations per year; median (IQR) | 1 (0–1) | 0 (0–1) | 0.115 |
Characteristics of the COPD cohort
Variables | COPD patients (n = 213) |
---|---|
Male, n (%) | 193 (90.6) |
Age, years (mean ± SD) | 73.1 ± 8.4 |
BMI (mean ± SD) | 23.57 ± 4.11 |
Cigarette smoking, n (%) | |
Current smoker | 80 (37.5) |
Ex-smoker | 113 (53.1) |
Never smoker | 20 (9.4) |
Comorbidities, n (%) | |
Heart failure | 17 (7.98) |
Coronary artery disease | 54 (25.35) |
Pulmonary hypertension | 28 (13.15) |
Lung cancer | 3 (1.4) |
Anxiety/depression | 9 (4.2) |
Osteoporosis | 12 (5.63) |
Malnutrition (BMI < 20) | 38 (17.84) |
Diabetes mellitus | 34 (15.96) |
OSA | 8 (3.76) |
Normocytic anemia | 26 (12.2) |
Lung fibrosis | 14 (6.57) |
Charlson comorbidity index score; median (IQR) | 5 (4–6) |
Hemogram values; median (IQR) | |
Leukocyte count | 7800 (6500–9400) |
Neutrophil, % | 62.9 (54.3–71.1) |
Eosinophil, % | 2.2 (1.0–4.0) |
Pulmonary function tests; median (IQR) | |
Post bronchodilator FEV1/FVC, % | 56 (40.2–72.2) |
Post bronchodilator FEV1, % | 56 (47–63.4) |
COPD subtypes, n (%) | |
GOLD I | 29 (13.6) |
GOLD II | 107 (50.2) |
GOLD III | 52 (24.4) |
GOLD IV | 25 (11.8) |
Group A | 112 (52.6) |
Group B | 39 (18.3) |
Group C | 21 (9.9) |
Group D | 41 (19.2) |
Treatment, n (%) | |
LABA + LAMA + ICS | 66 (30.99) |
LABA + LAMA | 76 (35.68) |
LABA + ICS | 18 (8.45) |
LAMA + ICS | 1 (0.47) |
LAMA only | 36 (16.9) |
LABA only | 12 (5.63) |
No inhaler treatment | 4 (1.88) |
ACO, n (%) | 19 (8.92) |
Exacerbations per year; median (IQR) | 1 (0–1) |
Neutrophilia was correlated with COPD comorbidities but not the frequency of moderate to severe exacerbations
Variables | Low cormobidity (n = 151) | High cormobidity (n = 62) | p value |
---|---|---|---|
Male, n (%) | 138 (91.4) | 55 (88.7) | 0.542 |
Age, years (mean ± SD) | 71.7 ± 8.6 | 75 ± 8.1 | 0.115 |
BMI (mean ± SD) | 23.9 ± 3.41 | 22.78 ± 5.41 | 0.026 |
Cigarette smoking, n (%) | 0.804 | ||
Current smoker | 58 (38.4) | 22 (35.5) | |
Ex-smoker | 80 (53.0) | 33 (53.2) | |
Never smoker | 13 (8.6) | 7 (11.3) | |
No. of comorbidities, median (IQR) | 1 (0–1) | 2 (2–3) | < 0.0001***a |
Comorbidities, n (%) | |||
Heart failure | 6 (4.0) | 11 (17.7) | < 0.001***a |
Coronary artery disease | 21 (13.9) | 33 (53.2) | < 0.001*** |
Pulmonary hypertension | 9 (6.0) | 19 (30.6) | < 0.001*** |
Lung cancer | 1 (0.7) | 2 (3.2) | 0.149 |
Anxiety/depression | 3 (2.0) | 6 (9.7) | 0.011* |
Osteoporosis | 5 (3.3) | 7 (11.3) | 0.022* |
Malnutrition (BMI < 20) | 15 (9.9) | 23 (37.1) | < 0.0001*** |
Diabetes mellitus | 12 (7.9) | 22 (35.5) | < 0.0001*** |
OSA | 1 (0.7) | 7 (11.3) | 0.0002** |
Anemia | 4 (2.6) | 22 (35.5) | < 0.0001*** |
Lung fibrosis | 6 (4.0) | 8 (12.9) | 0.017* |
Charlson comorbidity index score, median (IQR) | 4 (3–5) | 6 (5–7) | < 0.0001*** |
Hemogram values, median (IQR) | |||
Leukocyte count | 7500 (6300–9100) | 8300 (7175–11,000) | 0.0121* |
Neutrophil, % | 60 (52.9–68.2) | 70.6 (64.9–78.4) | < 0.0001*** |
Eosinophil, % | 2.5 (1.4–4.3) | 1.0 (0.5–3) | 0.0005*** |
Pulmonary function tests, median (IQR) | |||
Post bronchodilator FEV1/FVC% | 58 (49.1–64.2) | 51.8 (42.6–59.8) | 0.011* |
Post bronchodilator FEV1% | 60.5 (43–74.4) | 51.8 (32.8–63.8) | 0.004** |
COPD subtypes, n (%) | 0.012* | ||
COLD I | 22 (14.6) | 7 (11.3) | |
GOLD II | 82 (54.3) | 25 (40.3) | |
GOLD III | 36 (23.8) | 16 (25.8) | |
GOLD IV | 11 (7.3) | 14 (22.6) | |
COPD subtypes, n (%) | 0.0038** | ||
Group A | 90 (59.6) | 22 (35.5) | |
Group B | 25 (16.6) | 14 (22.6) | |
Group C | 15 (9.9) | 6 (9.7) | |
Group D | 21 (13.9) | 20 (32.3) | |
Treatment, n (%) | |||
LABA + LAMA + ICS | 44 (29.1) | 22 (35.5) | 0.363 |
LABA + LAMA | 53 (35.1) | 23 (37.1) | 0.782 |
LABA + ICS | 14 (9.3) | 4 (6.4) | 0.502 |
LAMA + ICS | 1 (0.7) | 0 (0) | 0.521 |
LAMA only | 24 (15.9) | 12 (19.4) | 0.540 |
LABA only | 11 (7.3) | 1 (1.6) | 0.103 |
No inhaler treatment | 4 (2.6) | 0 (0) | 0.196 |
ACO, n (%) | 16 (10.6) | 3 (4.8) | 0.181 |
Exacerbations per year, median (IQR) | 0 (0–1) | 1 (0–2) | 0.005** |